Drilldown: Medicines
Medicines > classes 
:
Anticonvulsant or
Antiparkinsonian or
[[:Category:Anticoagulants|Anticoagulant]]
:
Anticonvulsant or
Antiparkinsonian or
[[:Category:Anticoagulants|Anticoagulant]] Use the filters below to narrow your results.
generic:
Amantadine (1) ·
Apixaban (1) ·
Apomorphine (1) ·
Benztropine (1) ·
Biperiden (1) ·
Brivaracetam (1) ·
Bromocriptine (1) ·
Cabergoline (1) ·
Cannabidiol (1) ·
Carbidopa/levodopa (1) ·
Cenobamate (1) ·
Clobazam (1) ·
Entacapone (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fosphenytoin (1) ·
Lacosamide (1) ·
Levodopa (1) ·
Opicapone (1) ·
Perampanel (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Rasagiline (1) ·
Rivaroxaban (1) ·
Rotigotine (1) ·
Rufinamide (1) ·
Safinamide (1) ·
Selegiline (1) ·
Stiripentol (1) ·
Tiagabine (1) ·
Tolcapone (1) ·
Trihexyphenidyl (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Warfarin (1) ·
Zonisamide (1)
brand:
None (1) ·
Akineton (1) ·
Apokyn (1) ·
Aptiom (1) ·
Artane (1) ·
Azilect (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Cogentin (1) ·
Comtan (1) ·
Coumadin (discontinued in US but name in common use), Jantoven (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Dostinex (1) ·
Eldepryl (1) ·
Eliquis (1) ·
Epidiolex (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Luminal (1) ·
Neupro (1) ·
Onfi (1) ·
Ongentys (1) ·
Parlodel (1) ·
Sabril (1) ·
Sinemet (1) ·
Symmetrel (1) ·
Tasmar (1) ·
Vimpat (1) ·
Xadago (1) ·
Xarelto (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
AMPA receptor antagonist (1) ·
Central and peripheral COMT inhibitor (1) ·
D1/D2/D3 receptor agonist (1) ·
D2 agonist; D1 partial agonist (1) ·
D2 receptor agonist (1) ·
Dopamine precursor (1) ·
Dopamine precursor + DOPA decarboxylase inhibitor (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Irreversible selective MAO-B inhibitor (2) ·
MAO-B inhibitor; sodium channel blocker; glutamate release inhibitor (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
Muscarinic receptor antagonist (1) ·
Muscarinic receptor antagonist; dopamine reuptake inhibitor (1) ·
NMDA antagonist; dopamine releasing agent (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Non-selective dopamine receptor agonist (1) ·
Once-daily COMT inhibitor (1) ·
Peripheral COMT inhibitor (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Selective M1 muscarinic antagonist (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
'"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) ·
'"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. (1)
uses:
None (35) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) ·
'"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1)
starting dose:
None (35) ·
NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) ·
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1) ·
Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
None (35) ·
~100% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) ·
~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)
pregnancy:
None (36) ·
'''Contraindicated in pregnancy''' (warfarin embryopathy, fetal hemorrhage) except in mechanical mitral valves where the maternal mortality of alternative agents may exceed fetal risk.'"`UNIQ--ref-00000022-QINU`"' (1) ·
Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 38 results in range #1 to #38.